Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study
In the real world, one in four patients treated with first-line pertuzumab, trastuzumab, chemotherapy, with or without local therapy, reached CR. Two third of patients with a CR were still free of progression after five years.
Authors
- Sandra M. E. Geurts (ORCID: https://orcid.org/0000-0002-4265-9968)
- Birgit E. P. J. Vriens
- Nan Ding (ORCID: https://orcid.org/0009-0002-3725-4269)
- Manon J. Pepels
- Vivianne C. G. Tjan‐Heijnen (ORCID: https://orcid.org/0000-0002-3935-7440)
- Kirsten N. A. Aaldering
- Joan B. Heijns
- Eline Boon (ORCID: https://orcid.org/0000-0002-9768-2911)
- M. Wouter Dercksen
- Linda van de Winkel
- Maaike de Boer (ORCID: https://orcid.org/0000-0002-2775-8351)
- Franchette van den Berkmortel
- Jolien Tol
- Aude J O de Fallois
- Natascha A. J. B. Peters
- Renee Visserman
Institutions
- Radboud University Nijmegen (NL)
- Maastricht University Medical Centre (NL)
- Catharina Ziekenhuis (NL)
- St.Jans Gasthuis Weert (NL)
- Amphia Ziekenhuis (NL)
- Elkerliek Ziekenhuis (NL)
- VieCuri Medisch Centrum (NL)
- Máxima Medisch Centrum (NL)
- Zuyderland Medisch Centrum (NL)
- Laurentius Ziekenhuis (NL)
- St. Anna Ziekenhuis (NL)
- Jeroen Bosch Ziekenhuis (NL)
Publication Details
- Journal
- The Breast
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1016/j.breast.2025.104583
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- ZonMw
- Universiteit Maastricht
- Maastricht Universitair Medisch Centrum
- China Scholarship Council
- European Society for Medical Oncology